Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms

Samah Alimam, Jessica Ann Timms, Claire N. Harrison, Richard Dillon, Tracey Mare, Hugues DeLavallade, Deepti Radia, Claire Woodley, Yvonne Francis, Katy Sanchez, Shahram Kordasti, Donal P. McLornan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

The seasonal influenza A vaccine is recommended for patients with myeloproliferative neoplasms (MPNs). We hypothesised that immune deregulation associated with MPNs may affect the immune response gained following vaccinations when compared to healthy controls. Using deep immunophenotyping with high-dimensional single-cell analysis and mass cytometry we could demonstrate an altered immune response in MPN patients following vaccination. We found that prior to vaccination, MPN patients had reduced numbers of naive CD4 T cells. Furthermore, at 3-weeks and 3-months post-vaccination there was evidence of both delayed and impaired B- and T-memory cells responses. Thus, although, the immune systems of MPN patients can 'recognise' the Influenza A vaccine, the response appears inferior compared to healthy controls.

Original languageEnglish
JournalBritish Journal of Haematology
DOIs
Publication statusAccepted/In press - 2020

Keywords

  • flu
  • influenza A
  • myeloproliferative disorder
  • vaccines

Fingerprint

Dive into the research topics of 'Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms'. Together they form a unique fingerprint.

Cite this